<DOC>
	<DOCNO>NCT02045030</DOCNO>
	<brief_summary>This Phase II multi-center exploratory study identify biomarkers predictive clinical response aflibercept patient metastatic colorectal cancer fail first-line therapy , consist oxaliplatin-containing regimen combination bevacizumab . Patients consent needle core biopsy liver metastatic lesion prior start treatment blood sample collect study patient treatment . An exploratory pharmacoeconomic analysis perform evaluate productivity loss , quality life resource utilization treatment aflibercept .</brief_summary>
	<brief_title>Study Identify Biomarkers Clinical Response Aflibercept Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This Phase II multi-center exploratory study identify biomarkers predictive clinical response aflibercept patient metastatic colorectal cancer fail first-line therapy , consist oxaliplatin-containing regimen combination bevacizumab . Patients consent needle core biopsy liver metastatic lesion prior start treatment . This study open primarily sit conduct Q-CROC-01 study ( NCT00984048 ) , colorectal cancer patient receive standard first-line treatment undergo biopsy liver metastatic lesion treatment resistance . The post-first-line treatment biopsy use pre-treatment biopsy trial . For patient participate Q-CROC-01 study , patient require undergo liver needle core biopsy metastatic lesion study treatment . Biopsies blood sample collect study patient . An exploratory pharmacoeconomic analysis perform evaluate productivity loss , quality life resource utilization treatment aflibercept . A total 52 patient enrol , primarily center participate Q-CROC-01 study . The trial close enrolment 42 evaluable pre-treatment tumor biopsy sample obtain . Accrual total patient population estimate take 24-36 month estimate start date February 2014 .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Histologically cytologically proven adenocarcinoma colon rectum , least one liver metastasis site available biopsy . 2 . Patients must receive one prior chemotherapeutic regimen metastatic disease . This prior chemotherapy must oxaliplatin contain regimen ( combination bevacizumab ) . Patients receive bevacizumab firstline treatment regimen may also consider . 3 . Metastatic disease amenable potentially curative treatment . 4 . Measurable metastatic disease evaluable disease . 5 . ECOG 0 1 . 6 . Normal coagulation profile ( PT , PTT , INR ) . 7 . Provide write consent investigational nature , study design , risk benefit study explain . 8 . Age ≥ 18 year . 1 . More 1 prior chemotherapy regimen metastatic colorectal cancer . Previous adjuvant FOLFOX base chemotherapy allow . 2 . Relapse adjuvant treatment within 6 month completion adjuvant chemotherapy . 3 . Less 42 day elapse prior major surgery time registration . 4 . Inadequate unusable tissue tissue available biopsy . 5 . Any follow within 3 month registration : Grade 34 gastrointestinal bleeding/hemorrhage , diverticulitis , pulmonary embolism , inflammatory infection bowel disease , treatment resistant peptic ulcer disease , colitis , erosive esophagitis gastritis , uncontrolled thromboembolic event . 6 . Prior intolerance bevacizumab due toxicity . 7 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency . 8 . Gilbert 's Syndrome . 9 . Occurrence deep vein thrombosis within 4 week , prior registration . 10 . Any follow within 6 month prior registration ; myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , NYHA class III IV congestive heart failure , stroke transient ischemic attack . 11 . Contraindication component FOLFIRI chemotherapy regimen , per investigator ' judgement . 12 . Inadequate bone marrow function follow : Absolute neutrophil count ( ANC ) &lt; 1.5x 109/L Platelet count &lt; 100 x 109/L Hemoglobin &lt; 90 g/L 13 . Inadequate liver function test : Total bilirubin &gt; 1.5 x ULN Transaminases &gt; 3 x ULN ( liver metastasis present , 5 x ULN ) Alkaline phosphatase &gt; 3 x ULN ( liver metastasis present , 5 x ULN ) 14 . Contraindication aflibercept . Including : Urine proteincreatinine ratio ( UPCR ) &gt; 1 morning spot urinalysis proteinuria &gt; 500 mg/24h Serum creatinine &gt; 1.5 x upper limit normal ( ULN ) . If creatinine 1.0 1.5 x ULN , creatinine clearance , calculate accord CockroftGault formula , &lt; 60 ml/min exclude patient . History uncontrolled hypertension , define blood pressure &gt; 150/100 mgHG ( grade ≥ 2 accord NCIC CTCAE v. 4.0 ) , systolic blood pressure &gt; 180 mmHG diastolic blood pressure &lt; 90 mmHG , least 2 repeated determination separate day within 3 month prior study enrollment . Patients anticoagulant therapy unstable dose warfarin and/or outortherapeutic range INR ( &gt; 3 ) within 4 week prior study entry . Evidence clinically significant bleed diathesis underlie coagulopathy ( eg . INR &gt; 1.5 without vitamin K antagonist therapy ) , nonhealing wound . 15 . Known active brain metastasis meningeal disease . 16 . Female patient pregnant breastfeeding . 17 . Patients reproductive potential ( male female ) agree use accepted form contraception study period 6 month follow completion study treatment . 18 . Concurrent treatment anticancer therapy ( palliative radiation allow patient must metastatic site available biopsy irradiate ) . 19 . Known infection HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>metastatic</keyword>
	<keyword>colorectal</keyword>
	<keyword>cancer</keyword>
	<keyword>aflibercept</keyword>
	<keyword>FOLFIRI</keyword>
</DOC>